Compare DexCom, Inc. (DXCM) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Icl Group Ltd — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Icl Group Ltd trades at $5.3 (market cap $6.94B). The key difference: DexCom, Inc. is far larger — about 4.9× Icl Group Ltd's market cap, and Icl Group Ltd pays a 3.86% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | ICL | |
|---|---|---|
Market Cap | $33.79B | $6.94B |
Sector | Health | Basic Materials |
52-Week High | $89.53 | $6.84 |
52-Week Low | $54.84 | $4.80 |
Enterprise Value | $33.24B | $9.58B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
ICL trades at $5.465, up 2.34% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating estimates, and revenue is projected to grow to $7.7B in 2026. Recent news highlights strong quarterly results and a senior notes offering. The stock shows a neutral sentiment from oscillators, while analyst consensus is entirely Hold.
The outlook is mixed; earnings beats and operational improvements support upside, but declining net margins and a unanimous Hold rating from analysts suggest limited near-term catalysts. Key risks include raw material cost pressures and foreign exchange volatility, which could impact profitability despite positive cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
